Exploration for novel biologic markers which predict progression and prognosis of prostate cancer based on chromosomal alterations.
Project/Area Number |
16591579
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Akita University |
Principal Investigator |
TSUCHIYA Norihiko Akita University, School of Medicine, Associate Professor, 医学部, 助教授 (70282176)
|
Co-Investigator(Kenkyū-buntansha) |
HABUCHI Tomonori Akita University, School of Medicine, Professor, 医学部, 教授 (00293861)
HORIKAWA Yohei Akita University, School of Medicine, Research Associate, 医学部, 助手 (40361232)
|
Project Period (FY) |
2004 – 2005
|
Project Status |
Completed (Fiscal Year 2005)
|
Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2005: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 2004: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
Keywords | Prostate cancer / Chromosomal alteration / Genetic polymorphism |
Research Abstract |
The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer. One hundred and eleven prostate cancer patients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with GENESCAN software. Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over 7 [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = 0.016 and 0.025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = 0.019 or 0.026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = 0.001). The prognosis of metastatic prostate cancer patients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancer patients with bone metastasis at the diagnosis.
|
Report
(3 results)
Research Products
(10 results)